Strategic Partnerships Leverage Molecular Partners’ active radiopharmaceutical collaborations (Orano Med, Eckert & Ziegler, Pantera) to position co-development opportunities, licensing deals, and joint ventures around Radio-DARPin platforms for radioligand therapy pipelines.

Targeted Therapies Focus sales pitches on DLL3-targeting MP0712 and Radio-DARPin approaches to oncology customers seeking alternatives to conventional modalities, highlighting imaging/dosimetry data from compassionate care programs and ongoing US multicenter trials.

Radio-DARPin Advantage Emphasize the isotope-agnostic Radio-DARPin platform to potential partners in radiopharmaceutical manufacturing and isotope supply, underscoring opportunities across 225Ac and 212Pb value chains for expanded target landscapes.

Clinical-Stage Footing Position Molecular Partners as a nimble, clinically driven partner with ongoing Phase 1/2a activities and preclinical programs, suitable for tiered collaboration models, speed-to-co-development, and risk-sharing arrangements.

Market & Events Leverage recent conference presence (Gordon Research Conference, SNMMI, ASCO) to coordinate targeted outreach to oncology centers, radiopharmacy networks, and pharma BD teams attending these events for immediate follow-ups and demos.